查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1423675

到 2030 年阴道炎治疗药物市场预测：按疾病类型、治疗、分销管道和地区进行的全球分析

Vaginitis Therapeutics Market Forecasts to 2030 - Global Analysis By Disease Type, By Treatment, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球阴道炎治疗药物市场规模为 35.2 亿美元，预计预测期内复合年增长率为 10.3%，到 2030 年将达到 70.1 亿美元。

阴道炎药物包括旨在治疗阴道发炎和称为阴道炎的感染的医疗干预措施。常见原因包括细菌、真菌和病毒感染，治疗通常涉及抗生素、抗真菌药物和抗病毒药物。此外，管理荷尔蒙失衡和刺激物等潜在因素也很重要。个人化护理包括局部和内服药物药物、生活方式的改变以及解决影响因素以缓解症状和恢復阴道健康。

根据 CDC 的数据，大约 30% 的美国女性经常患有阴道炎。

提高对女性健康和阴道炎的认识

提高对女性健康和阴道感染疾病的认识已成为阴道炎治疗的重要动力。它提倡积极主动的医疗保健方法，鼓励妇女及早发现症状、及时就医并采取预防措施。这种意识将促进教育倡议，鼓励公开讨论，并减少围绕阴道健康问题的耻辱。这会改善就医行为、早期诊断和及时干预，从而推动对有效治疗方法的需求。

有限的医疗服务

医疗机会有限是阴道炎治疗药物的重要阻碍因素。存在障碍，包括医疗保健基础设施不足，特别是在农村和服务不足地区，以及医疗设施和专家的数量减少。此外，经济限制和获取机会的差异使一些人无法得到及时的诊断和治疗。这些限制加剧了诊断不足和治疗延误，并阻碍了重要资讯和治疗方法的普及，从而限制了受影响人群中阴道炎的有效治疗。

远端医疗的普及将加速

由于远距医疗与远距离诊断和治疗的结合，远端医疗的日益普及为阴道炎治疗药物市场带来了机会。随着远端医疗的扩展，需要准确的辐射监测工具。这些设备透过远端评估远端医疗期间的辐射暴露（包括诊断影像和放射治疗），对于确保患者安全至关重要。支援远端医疗的辐射检测技术创新为开发便携式、易于使用且准确的检测器以开拓这一新兴市场提供了机会。

临床试验挑战

有限的教育和资源阻碍了适当辐射安全措施的实施和对检测技术的理解。因此，患者和医护人员遭受辐射过度的风险增加，可能会产生健康后果。此外，缺乏严格的法规和基础设施投资不足进一步加剧了这一问题，可能导致与辐射相关的健康併发症率更高，以及对先进检测解决方案的需求不足，从而阻碍了市场成长。

COVID-19 的影响：

COVID-19 的爆发正在透过改变医疗保健优先事项来影响市场。由于医疗保健系统专注于大流行病的防范，注意力和资源已经从阴道炎等非紧急情况转移。医疗保健取得、供应链和患者行为的中断也影响了诊断和寻求治疗的模式，从而影响了大流行期间阴道炎治疗的市场动态。

处方药市场预计将在预测期内成为最大的市场

由于慢性病盛行率不断上升以及对专门医疗干预措施的需求不断增加，因此处方药细分市场预计在预测期内将成长最快。随着医疗保健意识的提高，对解决特定健康问题的处方药的需求激增。此外，监管部门的核准和药物研究的进步也促进了这一领域的崛起。

预计在线药房领域在预测期内将出现最高的复合年增长率

由于医疗保健服务的数位化、便利性和可及性不断提高，预计线上药局产业在预测期内将实现高成长率。线上药局提供了一个有吸引力的解决方案，因为消费者优先考虑在舒适的家中购买药品的便利性。远端医疗的采用和电子商务的进步正在推动该领域的快速成长。

比最大的地区

北美能够主导市场，主要是因为其先进的医疗基础设施、较高的意识以及对女性健康的关注。该地区领先的市场份额得到了成熟的研发活动、强大的法规结构以及积极采用创新治疗方法的进一步支持。阴道炎盛行率的不断上升，加上人口老化的加剧，增加了对有效治疗方法的需求，使北美成为在阴道炎治疗药物市场上占据最大市场占有率的关键参与者。我们正在加强我们的作用。

复合年增长率最高的地区：

由于意识的提高、医疗保健基础设施的增加以及对女性健康的日益关注，亚太地区正在经历强劲的市场成长。医疗保健服务的改善、生活方式的改变以及阴道炎盛行率上升等因素促进了该地区的扩张态势。此外，医学研究和技术的进步，加上政府的支持倡议，为市场开拓和创新阴道炎治疗方法的采用创造了有利的环境，推动了亚太地区市场的显着成长。

提供免费客製化：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球阴道炎治疗药物市场：依疾病类型

  • 萎缩性阴道炎
  • 细菌性阴道炎（BV）
  • 滴虫病
  • 外阴阴道念珠菌症(​​VVC)
  • 其他疾病类型

第六章全球阴道炎治疗药物市场：依治疗分类

  • 处方药
  • 天然和草药疗法
  • 成药(OTC)
  • 益生菌和阴道塞剂

第七章全球阴道炎治疗药物市场：按分销管道

  • 医院药房
  • 零售药房
  • 网路药房
  • 其他分销管道

第八章全球阴道炎治疗药物市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第九章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章 公司简介

  • Astellas Pharma
  • AstraZeneca PLC
  • Bausch Health Companies Inc
  • Bayer AG
  • Biocon Limited
  • Cipla Inc.
  • Ferring Pharmaceuticals
  • GlaxoSmithKline plc
  • Hologic, Inc.
  • Johnson & Johnson
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • TherapeuticsMD, Inc.
Product Code: SMRC24909

According to Stratistics MRC, the Global Vaginitis Therapeutics Market is accounted for $3.52 billion in 2023 and is expected to reach $7.01 billion by 2030 growing at a CAGR of 10.3% during the forecast period. Vaginitis therapeutics encompasses medical interventions aimed at treating inflammation or infection of the vagina, a condition known as vaginitis. Common causes include bacterial, fungal or viral infections and treatment often involves antimicrobial medications, antifungals, or antivirals. Additionally, managing underlying factors like hormonal imbalances or irritants is crucial. Personalized care may include topical or oral medications, lifestyle modifications and addressing contributing factors to alleviate symptoms and restore vaginal health.

According to the CDC, about 30% of women in the U.S. experience vaginitis at frequent intervals.

Market Dynamics:

Driver:

Heightened awareness about women's health and vaginal infections

Increased awareness about women's health and vaginal infections acts as a pivotal driver in vaginitis therapeutics. It fosters a proactive approach to healthcare, encouraging women to recognize symptoms early, seek prompt medical attention and adopt preventive measures. This awareness promotes education initiatives, facilitates open discussions and reduces stigma surrounding vaginal health issues. Consequently, it leads to improved healthcare-seeking behaviour, earlier diagnosis, and timely intervention, driving the demand for effective therapies.

Restraint:

Limited healthcare access

Limited healthcare access serves as a significant restraint in vaginitis therapeutics. It encompasses various barriers such as inadequate healthcare infrastructure, especially in rural or underserved areas, leading to reduced availability of medical facilities and specialists. Additionally, financial constraints and disparities in access prevent some individuals from seeking timely diagnosis and treatment. This limitation exacerbates underdiagnosis, delays in care and impedes the dissemination of crucial information and treatments, thereby restricting effective management of vaginitis among affected populations.

Opportunity:

Increasing adoption of telemedicine facilitates

The growing adoption of telehealth presents an opportunity in the vaginitis therapeutics market due to its integration with remote diagnostics and treatments. As telehealth expands, there is a need for accurate radiation monitoring tools. These devices become crucial in ensuring patient safety by remotely assessing radiation exposure during telemedicine sessions involving imaging or radiation therapies. Innovations in radiation detection technologies catering to telehealth settings offer a chance for companies to develop portable, user-friendly, and precise detectors, thereby tapping into this evolving market demand.

Threat:

Clinical trial challenges

Limited education and resources hinder the adoption of proper radiation safety measures and the understanding of detection technologies. This can lead to increased risks of overexposure to radiation for both patients and healthcare workers, impacting their health. Additionally, the absence of stringent regulations and insufficient infrastructure investment further exacerbate this issue, potentially resulting in higher incidences of radiation-related health complications and impeding the market's growth due to a lack of demand for advanced detection solutions.

Covid-19 Impact:

The COVID-19 pandemic has influenced the market by altering healthcare priorities. With healthcare systems focusing on combating the pandemic, attention and resources shifted away from non-emergency conditions like vaginitis. Disruptions in healthcare access, supply chains, and patient behaviour also affected diagnosis and treatment-seeking patterns, impacting the market dynamics for vaginitis therapeutics during the pandemic period.

The prescription drugs segment is expected to be the largest during the forecast period

The prescription drugs segment is anticipated to be the largest during the forecast period owing to the growing prevalence of chronic diseases and the increasing need for specialized medical interventions. As healthcare awareness rises, there is a surge in demand for prescription medications to address specific health conditions. Additionally, regulatory approvals and advancements in pharmaceutical research contribute to the prominence of this segment.

The online pharmacies segment is expected to have the highest CAGR during the forecast period

The online pharmacies segment is projected to achieve a high growth rate during the forecast period due to increasing digitalization, convenience and accessibility of healthcare services. As consumers prioritise the ease of purchasing medications from the comfort of their homes, online pharmacies offer a compelling solution. The adoption of telemedicine, coupled with advancements in e-commerce, fosters the rapid growth of this segment.

Region with largest share:

North America is positioned to dominate the market, primarily attributed to advanced healthcare infrastructure, high awareness levels, and a robust emphasis on women's health. The region's leading market share is further propelled by well-established research and development activities, a strong regulatory framework, and a proactive approach toward adopting innovative therapies. Increasing incidences of vaginitis, coupled with a growing aging population, contribute to the demand for effective therapeutics, reinforcing North America's pivotal role in capturing the largest market share in the vaginitis therapeutics market.

Region with highest CAGR:

The Asia-Pacific region is experiencing significant growth in the market due to rising awareness, increasing healthcare infrastructure and a growing emphasis on women's health. Factors such as improved access to healthcare services, changing lifestyles, and a rising incidence of vaginitis contribute to the region's poised expansion. Additionally, advancements in medical research and technology, coupled with supportive government initiatives, create a favourable environment for the development and adoption of innovative vaginitis therapeutics, driving substantial market growth in the Asia-Pacific region.

Key players in the market

Some of the key players in Vaginitis Therapeutics Market include Astellas Pharma, AstraZeneca PLC, Bausch Health Companies Inc, Bayer AG, Biocon Limited, Cipla Inc., Ferring Pharmaceuticals, GlaxoSmithKline plc, Hologic, Inc., Johnson & Johnson, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Mylan N.V., Novartis AG, Perrigo Company plc, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. and TherapeuticsMD, Inc.

Key Developments:

In January 2023, Astellas Pharma acquired Shionogi & Co.'s global women's health franchise, which includes the Vagifem vaginal ring for the treatment of recurrent vulvovaginal candidiasis (RVVC).

In May 2022, Bayer acquired FemTec, including Vagisan, a vaginal moisturizer. Additionally, Seres Therapeutics introduced SER-109, a microbiome-based therapy for recurrent vulvovaginal candidiasis (RVVC).

In April 2022, Pfizer introduced Daivobet, a topical cream combining steroids and vitamin D, designed to treat vulvovaginal candidiasis (VVC). Daivobet stands as the sole FDA-approved topical cream with this combination for VVC treatment.

Disease Types Covered:

  • Atrophic Vaginitis
  • Bacterial vaginosis (BV)
  • Trichomoniasis
  • Vulvovaginal Candidiasis (VVC)
  • Other Disease Types

Treatments Covered:

  • Prescription Drugs
  • Natural and Herbal Remedies
  • Over-the-counter (OTC) Drugs
  • Probiotics and Vaginal Suppositories

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Vaginitis Therapeutics Market, By Disease Type

  • 5.1 Introduction
  • 5.2 Atrophic Vaginitis
  • 5.3 Bacterial vaginosis (BV)
  • 5.4 Trichomoniasis
  • 5.5 Vulvovaginal Candidiasis (VVC)
  • 5.6 Other Disease Types

6 Global Vaginitis Therapeutics Market, By Treatment

  • 6.1 Introduction
  • 6.2 Prescription Drugs
  • 6.3 Natural and Herbal Remedies
  • 6.4 Over-the-counter (OTC) Drugs
  • 6.5 Probiotics and Vaginal Suppositories

7 Global Vaginitis Therapeutics Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacies
  • 7.3 Retail Pharmacies
  • 7.4 Online Pharmacies
  • 7.5 Other Distribution Channels

8 Global Vaginitis Therapeutics Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Astellas Pharma
  • 10.2 AstraZeneca PLC
  • 10.3 Bausch Health Companies Inc
  • 10.4 Bayer AG
  • 10.5 Biocon Limited
  • 10.6 Cipla Inc.
  • 10.7 Ferring Pharmaceuticals
  • 10.8 GlaxoSmithKline plc
  • 10.9 Hologic, Inc.
  • 10.10 Johnson & Johnson
  • 10.11 Lupin Pharmaceuticals, Inc.
  • 10.12 Merck & Co., Inc.
  • 10.13 Mylan N.V.
  • 10.14 Novartis AG
  • 10.15 Perrigo Company plc
  • 10.16 Pfizer Inc.
  • 10.17 Sanofi
  • 10.18 Sun Pharmaceutical Industries Ltd.
  • 10.19 Teva Pharmaceutical Industries Ltd.
  • 10.20 TherapeuticsMD, Inc.

List of Tables

  • Table 1 Global Vaginitis Therapeutics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Vaginitis Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 3 Global Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2021-2030) ($MN)
  • Table 4 Global Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2021-2030) ($MN)
  • Table 5 Global Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2021-2030) ($MN)
  • Table 6 Global Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2021-2030) ($MN)
  • Table 7 Global Vaginitis Therapeutics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 8 Global Vaginitis Therapeutics Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 9 Global Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2021-2030) ($MN)
  • Table 10 Global Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2021-2030) ($MN)
  • Table 11 Global Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2021-2030) ($MN)
  • Table 12 Global Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2021-2030) ($MN)
  • Table 13 Global Vaginitis Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 14 Global Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 15 Global Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 16 Global Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 17 Global Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 18 North America Vaginitis Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 19 North America Vaginitis Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 20 North America Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2021-2030) ($MN)
  • Table 21 North America Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2021-2030) ($MN)
  • Table 22 North America Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2021-2030) ($MN)
  • Table 23 North America Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2021-2030) ($MN)
  • Table 24 North America Vaginitis Therapeutics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 25 North America Vaginitis Therapeutics Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 26 North America Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2021-2030) ($MN)
  • Table 27 North America Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2021-2030) ($MN)
  • Table 28 North America Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2021-2030) ($MN)
  • Table 29 North America Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2021-2030) ($MN)
  • Table 30 North America Vaginitis Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 31 North America Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 32 North America Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 33 North America Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 34 North America Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 35 Europe Vaginitis Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 36 Europe Vaginitis Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 37 Europe Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2021-2030) ($MN)
  • Table 38 Europe Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2021-2030) ($MN)
  • Table 39 Europe Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2021-2030) ($MN)
  • Table 40 Europe Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2021-2030) ($MN)
  • Table 41 Europe Vaginitis Therapeutics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 42 Europe Vaginitis Therapeutics Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 43 Europe Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2021-2030) ($MN)
  • Table 44 Europe Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2021-2030) ($MN)
  • Table 45 Europe Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2021-2030) ($MN)
  • Table 46 Europe Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2021-2030) ($MN)
  • Table 47 Europe Vaginitis Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 48 Europe Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 49 Europe Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 50 Europe Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 51 Europe Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 52 Asia Pacific Vaginitis Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 53 Asia Pacific Vaginitis Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 54 Asia Pacific Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2021-2030) ($MN)
  • Table 55 Asia Pacific Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2021-2030) ($MN)
  • Table 56 Asia Pacific Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2021-2030) ($MN)
  • Table 57 Asia Pacific Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2021-2030) ($MN)
  • Table 58 Asia Pacific Vaginitis Therapeutics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 59 Asia Pacific Vaginitis Therapeutics Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 60 Asia Pacific Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2021-2030) ($MN)
  • Table 61 Asia Pacific Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2021-2030) ($MN)
  • Table 62 Asia Pacific Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2021-2030) ($MN)
  • Table 63 Asia Pacific Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2021-2030) ($MN)
  • Table 64 Asia Pacific Vaginitis Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 65 Asia Pacific Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 66 Asia Pacific Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 67 Asia Pacific Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 68 Asia Pacific Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 69 South America Vaginitis Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 70 South America Vaginitis Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 71 South America Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2021-2030) ($MN)
  • Table 72 South America Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2021-2030) ($MN)
  • Table 73 South America Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2021-2030) ($MN)
  • Table 74 South America Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2021-2030) ($MN)
  • Table 75 South America Vaginitis Therapeutics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 76 South America Vaginitis Therapeutics Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 77 South America Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2021-2030) ($MN)
  • Table 78 South America Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2021-2030) ($MN)
  • Table 79 South America Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2021-2030) ($MN)
  • Table 80 South America Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2021-2030) ($MN)
  • Table 81 South America Vaginitis Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 82 South America Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 83 South America Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 84 South America Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 85 South America Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 86 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 87 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 88 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2021-2030) ($MN)
  • Table 89 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2021-2030) ($MN)
  • Table 90 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2021-2030) ($MN)
  • Table 91 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2021-2030) ($MN)
  • Table 92 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 93 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 94 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2021-2030) ($MN)
  • Table 95 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2021-2030) ($MN)
  • Table 96 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2021-2030) ($MN)
  • Table 97 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2021-2030) ($MN)
  • Table 98 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 99 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 100 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 101 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 102 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)